Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer
The newly identified AEP/ATR/PPP1R10 axis plays a dual role in genomic stability and radiotherapy resistance in BC. Our work provides new clues to the underlying mechanisms of tumor resistance and strong evidence validating the AEP/ATR axis as a novel predictive biomarker and therapeutic target for the stratification and treatment of radioresistant BC patients.
Authors
- Colin Watts (ORCID: https://orcid.org/0000-0001-6183-2087)
- Mercedes Tomé (ORCID: https://orcid.org/0000-0001-8682-1800)
- Pablo Huertas (ORCID: https://orcid.org/0000-0002-1756-4449)
- Raúl V. Durán (ORCID: https://orcid.org/0000-0002-2249-9215)
- Macarena Morillo‐Huesca (ORCID: https://orcid.org/0000-0002-2914-4871)
- Gema Moreno‐Bueno (ORCID: https://orcid.org/0000-0002-5030-6687)
- Jonathan Martínez‐Fábregas (ORCID: https://orcid.org/0000-0001-5809-065X)
- Ryan Conesa-Bakkali
- Ignacio G. López-Cepero
Institutions
- Consejo Superior de Investigaciones Científicas (ES)
- University of Dundee (GB)
- Instituto de Salud Carlos III (ES)
- Instituto de Investigaciones Biomédicas Sols-Morreale (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Centro Andaluz de Biología Molecular y Medicina Regenerativa (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- MD Anderson Cancer Center Madrid (ES)
- Universidad Autónoma de Madrid (ES)
- Universidad de Sevilla (ES)
- Universidad Pablo de Olavide (ES)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1186/s13046-025-03334-6
- Citations
- 4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- University of Dundee
- Universidad de Sevilla
- Ministerio de Ciencia, Innovación y Universidades
- European Commission
- Ministerio de Ciencia e Innovación
- Junta de Andalucía
- Centro de Investigación Biomédica en Red de Cáncer
- University of Texas MD Anderson Cancer Center
- Instituto de Salud Carlos III
- European Regional Development Fund
- Agencia Estatal de Investigación